123 related articles for article (PubMed ID: 35419921)
1. In Situ Prodrug Activation by an Affibody-Ruthenium Catalyst Hybrid for HER2-Targeted Chemotherapy.
Zhao Z; Tao X; Xie Y; Lai Q; Lin W; Lu K; Wang J; Xia W; Mao ZW
Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202202855. PubMed ID: 35419921
[TBL] [Abstract][Full Text] [Related]
2. Degradable ZnS-Supported Bioorthogonal Nanozymes with Enhanced Catalytic Activity for Intracellular Activation of Therapeutics.
Zhang X; Lin S; Huang R; Gupta A; Fedeli S; Cao-Milán R; Luther DC; Liu Y; Jiang M; Li G; Rondon B; Wei H; Rotello VM
J Am Chem Soc; 2022 Jul; 144(28):12893-12900. PubMed ID: 35786910
[TBL] [Abstract][Full Text] [Related]
3. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
4. Siderophore-Linked Ruthenium Catalysts for Targeted Allyl Ester Prodrug Activation within Bacterial Cells.
Southwell JW; Herman R; Raines DJ; Clarke JE; Böswald I; Dreher T; Gutenthaler SM; Schubert N; Seefeldt J; Metzler-Nolte N; Thomas GH; Wilson KS; Duhme-Klair AK
Chemistry; 2023 Feb; 29(8):e202202536. PubMed ID: 36355416
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium-Containing Block Copolymer Assemblies: Red-Light-Responsive Metallopolymers with Tunable Nanostructures for Enhanced Cellular Uptake and Anticancer Phototherapy.
Sun W; Parowatkin M; Steffen W; Butt HJ; Mailänder V; Wu S
Adv Healthc Mater; 2016 Feb; 5(4):467-73. PubMed ID: 26680371
[TBL] [Abstract][Full Text] [Related]
6. A platinum-ruthenium hybrid prodrug with multi-enzymatic activities for chemo-catalytic therapy of hypoxic tumors.
Yang GG; Su XX; Liang BB; Pan ZY; Cao Q; Mao ZW
Chem Sci; 2022 Oct; 13(38):11360-11367. PubMed ID: 36320579
[TBL] [Abstract][Full Text] [Related]
7. Designing luminescent ruthenium prodrug for precise cancer therapy and rapid clinical diagnosis.
Zhao Z; Zhang X; Li CE; Chen T
Biomaterials; 2019 Feb; 192():579-589. PubMed ID: 30551086
[TBL] [Abstract][Full Text] [Related]
8. Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release.
Hufziger KT; Thowfeik FS; Charboneau DJ; Nieto I; Dougherty WG; Kassel WS; Dudley TJ; Merino EJ; Papish ET; Paul JJ
J Inorg Biochem; 2014 Jan; 130():103-11. PubMed ID: 24184694
[TBL] [Abstract][Full Text] [Related]
9. Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
Lan KH; Tsai CL; Chen YY; Lee TL; Pai CW; Chao Y; Lan KL
Biochem Biophys Res Commun; 2021 Dec; 582():137-143. PubMed ID: 34710829
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer.
Zhang C; Zhang F; Han M; Wang X; Du J; Zhang H; Li W
Sci Rep; 2020 Dec; 10(1):22015. PubMed ID: 33328545
[TBL] [Abstract][Full Text] [Related]
11. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.
Wentworth P; Datta A; Blakey D; Boyle T; Partridge LJ; Blackburn GM
Proc Natl Acad Sci U S A; 1996 Jan; 93(2):799-803. PubMed ID: 8570638
[TBL] [Abstract][Full Text] [Related]
12. Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents.
Pal M; Nandi U; Mukherjee D
Eur J Med Chem; 2018 Apr; 150():419-445. PubMed ID: 29547831
[TBL] [Abstract][Full Text] [Related]
13. Light-activated ruthenium (II)-bicalutamide prodrugs for prostate cancer.
Zhao J; Liu N; Sun S; Gou S; Wang X; Wang Z; Li X; Zhang W
J Inorg Biochem; 2019 Jul; 196():110684. PubMed ID: 31054419
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Role of Inter- and Intramolecular Promoters in Electro- and Photochemical CO
Fujita E; Grills DC; Manbeck GF; Polyansky DE
Acc Chem Res; 2022 Mar; 55(5):616-628. PubMed ID: 35133133
[TBL] [Abstract][Full Text] [Related]
15. A DNA-Gated and Self-Protected Bioorthogonal Catalyst for Nanozyme-Assisted Safe Cancer Therapy.
Zhang Y; Zhang L; Wang W; Deng Q; Liu M; Zhu Z; Liu H; Ren J; Qu X
Angew Chem Int Ed Engl; 2023 Aug; 62(32):e202306395. PubMed ID: 37268594
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-Responsive Mesoporous Ruthenium for Combined Chemo-Photothermal Therapy of Drug-Resistant Bacteria.
Liu Y; Lin A; Liu J; Chen X; Zhu X; Gong Y; Yuan G; Chen L; Liu J
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26590-26606. PubMed ID: 31264823
[TBL] [Abstract][Full Text] [Related]
17. Chemical Activation in Blood Serum and Human Cell Culture: Improved Ruthenium Complex for Catalytic Uncaging of Alloc-Protected Amines.
Völker T; Meggers E
Chembiochem; 2017 Jun; 18(12):1083-1086. PubMed ID: 28425643
[TBL] [Abstract][Full Text] [Related]
18. Gold nanorod-loaded thermosensitive liposomes facilitate the targeted release of ruthenium(II) polypyridyl complexes with anti-tumor activity.
Zhu L; Kuang Z; Song P; Li W; Gui L; Yang K; Ge F; Tao Y; Zhang W
Nanotechnology; 2021 Aug; 32(45):. PubMed ID: 34352731
[TBL] [Abstract][Full Text] [Related]
19. Is the ruthenium analogue of compound I of cytochrome p450 an efficient oxidant? A theoretical investigation of the methane hydroxylation reaction.
Sharma PK; De Visser SP; Ogliaro F; Shaik S
J Am Chem Soc; 2003 Feb; 125(8):2291-300. PubMed ID: 12590559
[TBL] [Abstract][Full Text] [Related]
20. Catalytic wet oxidation of aqueous methylamine: comparative study on the catalytic performance of platinum-ruthenium, platinum, and ruthenium catalysts supported on titania.
Song A; Lu G
Environ Technol; 2015; 36(9-12):1160-6. PubMed ID: 25358013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
